COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Prospective Pharmacodynamic Study of Rivaroxaban

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01743898
Recruitment Status : Completed
First Posted : December 6, 2012
Last Update Posted : August 4, 2014
Information provided by (Responsible Party):
Suzanne J. Francart, PharmD, CPP, University of North Carolina, Chapel Hill

Brief Summary:
The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of coagulation tests to therapeutic doses of rivaroxaban may be helpful in better understanding abnormal responses to rivaroxaban. The purpose of the study is to define a therapeutic reference range for peak and trough coagulation tests in patients taking FDA approved doses of rivaroxaban and to determine which tests may be most clinically useful for monitoring rivaroxaban.

Condition or disease Intervention/treatment
Blood Clot Drug: Rivaroxaban Other: no anticoagulation

Layout table for study information
Study Type : Observational
Estimated Enrollment : 65 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: A Prospective Pharmacodynamic Study of Rivaroxaban Using Peak and Trough Coagulation Test Results in Patients on Therapeutic Doses of Rivaroxaban
Study Start Date : October 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban

Group/Cohort Intervention/treatment
Patient taking FDA approved dose of rivaroxaban
Drug: Rivaroxaban
Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
Other Name: Xarelto

Control Group
Patient not taking any form of anticoagulation
Other: no anticoagulation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients taking FDA-approved doses of rivaroxaban and control subjects not taking an anticoagulant or antiplatelet were eligible for inclusion

Inclusion Criteria:

Person taking therapeutic dose of Rivaroxaban

Exclusion Criteria:

  • CrCl < 15 mL/min
  • Non-FDA approved dose based on calculated CrCl with most recent SCr
  • Age < 18 years
  • Inability to communicate in the English language
  • Decisionally-impaired individuals
  • Incarcerated
  • Pregnant/Lactating (Pregnancy category: C, unevaluated effects in lactation)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01743898

Layout table for location information
United States, North Carolina
Carolina Point II
Chapel Hill, North Carolina, United States, 27514
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Layout table for investigator information
Study Director: Emily Hawes, PharmD, BCPS, CPP Department of Family Medicine
Layout table for additonal information
Responsible Party: Suzanne J. Francart, PharmD, CPP, Pharm. D, CPP, University of North Carolina, Chapel Hill Identifier: NCT01743898    
Other Study ID Numbers: 12-1254
First Posted: December 6, 2012    Key Record Dates
Last Update Posted: August 4, 2014
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action